Liver microwave ablation: a systematic review of various FDA-approved systems
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1084
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Liver microwave ablation: a systematic review of various FDA-approved systems ; day:30 ; month:11 ; year:2018 ; pages:1-10
European radiology ; (30.11.2018), 1-10
- Urheber
-
Ruiter, Simeon J. S.
Heerink, Wouter J.
Jong, Koert P. de
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00330-018-5842-z
- URN
-
urn:nbn:de:101:1-2019011721360056576815
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ruiter, Simeon J. S.
- Heerink, Wouter J.
- Jong, Koert P. de
- SpringerLink (Online service)
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
Synthesis of the First FDA-Approved HIV Protease Inhibitor
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Identification of FDA-approved drugs targeting the Farnesoid X Receptor
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans